COVID-19 Vaccine Response in People with MS Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab or Interferon Therapy
Background: COVID-19 is a potentially fatal respiratory illness, caused by the novel coronavirus, SARS-CoV-2, which developed into the...
Spasticity Experience in Adults with Multiple Sclerosis: An Integrated Conceptual Model
Background: Spasticity is a common symptom of multiple sclerosis (MS), often leading to functional limitations and disability. Objectives:...
Exploring the Impact of the COVID-19 Pandemic on Social Isolation and Mental Health in People with MS
Background: People with Multiple Sclerosis (MS) may be disproportionally impacted by COVID-19 as various factors important to their...
Optical Coherence Tomography As a Biomarker for Multiple Sclerosis Studies
Background: Optic Neuritis occurs in about 20% of MS patients as the initial symptom. Objectives: To assess the clinical utility of optical...
Accurate Cervical Spinal Cord Area Measurements Can be Extracted from Brain Images
Background: Multiple Sclerosis (MS) is an inflammatory, demyelinating disease with neurodegeneration in the central nervous system. Spinal...
Stakeholder Recommendations for a Dyadic Physical Activity Intervention for People with Moderate-to-Severe Multiple Sclerosis and Their Care-Partners: A Modified e-Delphi Study.
Background: People with moderate-to-severe multiple sclerosis (MS) and their family caregivers do not engage in sufficient physical...
International Magnims-CMSC-Naims Consensus Recommendations on the Use of Standardized MRI in MS
Background: Standardized magnetic resonance imaging (MRI) guidelines published in 2015 by the MAGNIMS group and in 2016 by the CMSC are...